Cargando…
Guideline on safety evaluation of cell-based medicinal products for animal use
With the increased use of cell therapy in the veterinary sector, there is a growing demand for the development of cell-based medicinal products and the determination of their safety. Currently, the Korean Animal and Plant Quarantine Agency has established a guideline for evaluating the safety of cel...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Veterinary Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441815/ https://www.ncbi.nlm.nih.gov/pubmed/30944536 http://dx.doi.org/10.4142/jvs.2019.20.e14 |
_version_ | 1783407605998157824 |
---|---|
author | Ku, Hyun-Ok Yi, Hee Park, Young-Il Jeon, Byung-suk Kang, Hwan-Goo Kim, Yong-Sang Park, Bong-Kyun |
author_facet | Ku, Hyun-Ok Yi, Hee Park, Young-Il Jeon, Byung-suk Kang, Hwan-Goo Kim, Yong-Sang Park, Bong-Kyun |
author_sort | Ku, Hyun-Ok |
collection | PubMed |
description | With the increased use of cell therapy in the veterinary sector, there is a growing demand for the development of cell-based medicinal products and the determination of their safety. Currently, the Korean Animal and Plant Quarantine Agency has established a guideline for evaluating the safety of cell-based medicinal products for animal use. The guideline includes items related to definition, classification, management, manufacturing procedure and quality control (standard and test method), stability testing, toxicity testing, pharmacological testing, and performance of clinical trials. In addition, testing protocols related to safety assessment of animal cell-based products such as chromosome karyotyping, tumorigenicity testing, confirmatory testing of biodistribution and kinetics, and target animal safety testing are described in detail. Moreover, because cell-based medicinal products are novel therapies, deviations from traditional designs may be justified in order to obtain relevant safety information on the treatment. Additionally, this guideline can be amended on the basis of new scientific findings. |
format | Online Article Text |
id | pubmed-6441815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Korean Society of Veterinary Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-64418152019-04-03 Guideline on safety evaluation of cell-based medicinal products for animal use Ku, Hyun-Ok Yi, Hee Park, Young-Il Jeon, Byung-suk Kang, Hwan-Goo Kim, Yong-Sang Park, Bong-Kyun J Vet Sci Guideline With the increased use of cell therapy in the veterinary sector, there is a growing demand for the development of cell-based medicinal products and the determination of their safety. Currently, the Korean Animal and Plant Quarantine Agency has established a guideline for evaluating the safety of cell-based medicinal products for animal use. The guideline includes items related to definition, classification, management, manufacturing procedure and quality control (standard and test method), stability testing, toxicity testing, pharmacological testing, and performance of clinical trials. In addition, testing protocols related to safety assessment of animal cell-based products such as chromosome karyotyping, tumorigenicity testing, confirmatory testing of biodistribution and kinetics, and target animal safety testing are described in detail. Moreover, because cell-based medicinal products are novel therapies, deviations from traditional designs may be justified in order to obtain relevant safety information on the treatment. Additionally, this guideline can be amended on the basis of new scientific findings. The Korean Society of Veterinary Science 2019-03 2019-03-15 /pmc/articles/PMC6441815/ /pubmed/30944536 http://dx.doi.org/10.4142/jvs.2019.20.e14 Text en © 2019 The Korean Society of Veterinary Science https://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Guideline Ku, Hyun-Ok Yi, Hee Park, Young-Il Jeon, Byung-suk Kang, Hwan-Goo Kim, Yong-Sang Park, Bong-Kyun Guideline on safety evaluation of cell-based medicinal products for animal use |
title | Guideline on safety evaluation of cell-based medicinal products for animal use |
title_full | Guideline on safety evaluation of cell-based medicinal products for animal use |
title_fullStr | Guideline on safety evaluation of cell-based medicinal products for animal use |
title_full_unstemmed | Guideline on safety evaluation of cell-based medicinal products for animal use |
title_short | Guideline on safety evaluation of cell-based medicinal products for animal use |
title_sort | guideline on safety evaluation of cell-based medicinal products for animal use |
topic | Guideline |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441815/ https://www.ncbi.nlm.nih.gov/pubmed/30944536 http://dx.doi.org/10.4142/jvs.2019.20.e14 |
work_keys_str_mv | AT kuhyunok guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse AT yihee guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse AT parkyoungil guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse AT jeonbyungsuk guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse AT kanghwangoo guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse AT kimyongsang guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse AT parkbongkyun guidelineonsafetyevaluationofcellbasedmedicinalproductsforanimaluse |